q&more
My watch list
my.chemie.de  
Login  

Paradigm shift

Setting the course in genetic diagnostics and personalised medicine

Prof. Dr. Theo Dingermann (Johann Wolfgang Goethe-Universität Frankfurt (Main), Institut für Pharmazeutische Biologie)

What  would medicine be without drugs? But are these drugs being used optimally today? Not at all, as we now know thanks to the findings of molecular medicine. Because for  the use of these drugs, it is important to observe  two aspects: the disease and the patient. Only slowly  is it becoming possible to more and more include  patient-relevant information into a treatment decision.

Before a drug is authorized  for use in human beings, it is extensively tested  - initially in the most varied bio­chemical-pharmacological models in test-tubes or in an organ bath, then in diverse animal models and finally on test persons and patients. This tiered approach allows for reliable conclusions regarding the effectiveness and tolerability of the drug. And only when a benefit/risk analysis is clearly in favour of the benefits, will the drug be awarded access to the market via licensing by international or national authorities.

However, these statements are somewhat ambiguous in their details, since they are based on the formation of a more or less projected Gaussian distribution. This is what we have become accustomed to, because there is no alternative. However, were a large enough test population selected, this would show some radical “outliers”. Those affected by such a marginal population can, in some cases, have major problems with such a drug. This is because swings in the direction of “ineffectiveness” are just as possible as swings in the direction of individual overdose during, an in principle, correct application, which can be expressed as intolerance ­to the point of acute toxicity.

With the rapidly increasing demand for security in our society in  recent years, such individual swings, in terms of safety and efficacy, can place a drug itself at risk. An increase in  reports of insufficient efficacy, or side effects, though low in number yet  serious in effect can nowadays quickly lead to the loss of the licence. It is, therefore, in the interest of patients, as well as the pharmaceutical industry, to take measures to make such fluctuations in terms of efficacy and tolerability of a drug predictable and thereby preventable.

The causes of these individual deviations from the norm are differences in the genetic makeup of the patients. These can be such that, due to the possibility of physiological ­“detours”, the properties of a drug are cancelled out. They can also affect the functional units (enzymes and transporters), which naturally modify the active substance or grant  the drug access to the target structure.

Today it often possible, in principle, to recognise these deviations,  respective measures operate under the heading  “stratified medicine”. The consequences, which will result in the use of this technical potential, will amount to a paradigm shift. In due time we will see a change, from the treatment of a disease to the treatment of a patient with a specific genetic makeup.

Many examples have been listed where already today a therapy could be significantly optimised, if  therapy decisions were not only based on disease-related parameters but rather the patient-specific genetic parameters were also included. Diagnostics – and more than ever genetic diagnostics – ­receive  a new quality here: the traditional  terrain of disease-related diagnostic investigation will be supplemented by diagnostics that will reveal whether and how drugs may act on  a certain disease.

These new prospects would make good, existing  therapies in many ways even better - particularly for patients who, based on individual parameters, do not fall within the crown region of a Gaussian distribution of the outcome of  a clinical efficacy study.

Facts, background information, dossiers

  • diagnostics
  • medicine
  • drugs
  • personalized medicine
  • genetic diagnostics
  • drug safety

Other articles by these authors

All articles

Why biosimilars and not biogenerics?

Medicines produced using genetic techniques have existed since 2006, called “similar biological medicinal products” or “biosimilars”. Until a year ago, this was a fairly low-profile group (…)

More about Uni Frankfurt am Main

  • News

    How to brew high-value fatty acids with brewer's yeast

    Short-chain fatty acids are high-value constituents of cosmetics, active pharmaceutical ingredients, antimicrobial substances, aromas or soap. To date, it has only been possible to extract them from crude oil by chemical means or from certain plants, such as coconut, using a complex process ... more

    Starship Enterprise concept: Optical tractor beam traps bacteria

    Up to now, if scientists wanted to study blood cells, algae, or bacteria under the microscope, they had to mount these cells on a substrate such as a glass slide. Physicists at Bielefeld and Frankfurt Universities have developed a method that traps biological cells with a laser beam enablin ... more

  • q&more articles

    Why biosimilars and not biogenerics?

    Medicines produced using genetic techniques have existed since 2006, called “similar biological medicinal products” or “biosimilars”. Until a year ago, this was a fairly low-profile group, even in expert circles. This has all changed now, however, with the recent licensing of the first bios ... more

    Polar and a potential drinking water hazard

    In Germany, drinking water supplies are plentiful and generally of a high quality. Drinking water is in Germany most commonly produced from groundwater (69.6 %), with a further 12.4 % being taken from lakes and dam reservoirs. The proportion of drinking water processed from bank filtration ... more

  • Authors

    Prof. Dr. Heinfried H. Radeke

    Heinfried H. Radeke studied medicine at the Hannover Medical School (MHH) and received his medical license in 1985. His Ph.D. thesis was recognized as the best research dissertation of 1986. After two years as an assistant physician at the Göttingen University Hospital, he began his career ... more

    Prof. Dr. Theo Dingermann

    Theodor Dingermann, born 1948, studied pharmacy in Erlangen ­and received his doctor title in 1980 to become Dr. rer. nat. In 1990 he was offered the C4 professorship at the Institute for Pharmaceutical Biology, University of Frankfurt.  From 2000 to 2004 he was President of the German Phar ... more

    Prof. Dr. Wilhelm Püttmann

    Wilhelm Püttmann studied chemistry at RWTH Aachen and the University of Cologne. He received his doctorate in organic synthesis under Professor Emanuel Vogel in Cologne in 1980. Following two years of postdoctoral work, he moved to the field of geochemical analysis, assuming the leadership ... more

White paper

Product

Topics A-Z

All topics

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:



Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE